Alvotech, a global biotech company dedicated to developing and producing biosimilar medicines for patients worldwide, is proud to announce a new exclusive agreement with Polifarma Ilac San. ve tic. A.S. for the commercialization of AVT06, a proposed biosimilar to Eylea® (aflibercept), in Turkey. This new agreement marks a major milestone in Alvotech’s efforts to make innovative biosimilar medicines more accessible to those in need.
Alvotech is delighted to partner with Polifarma to bring a potential new therapy for eye disease to the Turkish market. Robert Wessman, Chairman and CEO of Alvotech, emphasizes the company’s commitment to providing better patient access to cost-effective biologics, and this agreement will ensure that patients in Turkey are able to benefit from cutting-edge treatments.
For 37 years, Polifarma has been devoted to improving public health and the health sector worldwide with the mission of ‘We stand by life’. We are thrilled to announce that our new agreement with Alvotech will enable us to further expand our portfolio and strengthen our presence in the ophthalmology area. This agreement will provide us with the opportunity to commercialize this product in Turkey and make a lasting impact on improving people’s lives.
Under the terms of the agreement, Alvotech will take care of development and production, while Polifarma will be responsible for market registration and commercialization of the product. Both partners are excited to work together to bring their joint venture to life and bring a much-needed product to the market.
Alvotech has taken a major step towards developing a biosimilar to Eylea® – AVT06. In July 2022, the company announced the launch of a clinical trial to compare the efficacy, safety and immunogenicity of AVT06 and Eylea® in adults suffering from neovascular (wet) age-related macular degeneration (AMD). This is a significant milestone for the field of biosimilars, potentially paving the way for more affordable treatments to help those affected by AMD.
About AVT06
AVT06 is an exciting investigational recombinant fusion protein that has the potential to be a biosimilar candidate to Eylea® (aflibercept). By binding vascular endothelial growth factors (VEGF) and inhibiting the binding and activation of VEGF receptors, AVT06 can help reduce neovascularization and vascular permeability. Although AVT06 has yet to receive regulatory approval, it offers an exciting opportunity to explore the potential of biosimilars.
About Polifarma
Polifarma is a leading brand in the Turkish health sector, with a 37-year history of 100% domestic capital. Their 77 thousand square meter facility in Ergene/Tekirdağ produces 350 million boxes per year, ranging from ampoules, vials, pre-filled syringes (PFS), and a range of 600 licensed products in 15 therapeutic areas.
As part of their commitment to quality and technology, they have achieved 12 certificates in the prescribed markets and are EU-GMP compliant. With innovative solutions such as Turkey’s first lipid product and the world’s first three-chamber parenteral nutrition solution and CAPD device, Polifarma are striving to become a global leader by 2025 and are currently exporting to 70 countries.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, that is dedicated to the development and manufacture of biosimilar medicines to improve the lives of patients around the world. With a fully integrated approach and broad in-house capabilities, Alvotech is aiming to become a leading force in the biosimilar space by providing high quality, cost-effective products and services.
The company’s current pipeline contains eight biosimilar candidates, which can treat a variety of conditions, such as autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer.
To ensure global reach and local expertise, Alvotech has formed strategic commercial partnerships with numerous leading organizations, including Teva Pharmaceuticals, STADA Arzneimittel AG, Fuji Pharma Co., Ltd, Advanz Pharma, Cipla/Cipla Gulf/Cipla Med Pro, JAMP Pharma Corporation, Yangtze River Pharmaceutical (Group) Co., Ltd., DKSH, YAS Holding LLC, Abdi Ibrahim, Kamada Ltd., Mega Labs, Stein, Libbs, Tuteur and Saval, and Lotus Pharmaceuticals Co., Ltd.
The partnerships cover unique products and territories and are crucial to Alvotech’s mission of providing affordable and quality healthcare to patients